Introduction
Materials and methods
Differential expression gene analysis of ICC and paracancerous tissues from TCGA datasets
Kaplan–Meier analysis of gene signature from TCGA datasets using the survival and survminer packages in R
Immune infiltration estimations using CIBERSORT, QUANTISEQ, and MCPCOUTER
Patients and tumor samples
Immunohistochemistry and quantification of CD68, SIRPα, PD1 and SIGLEC10 density
Follow-up and survival analysis of ICC patients
Statistical analysis
Results
Identification of differentially expressed mRNAs and signal pathways of ICCs
Analyses of cell type proportion, M1, M2 markers and phagocytosis checkpoints between normal and cancer tissues
Prognostic factors of differentially expressed M1 and M2 markers and phagocytosis checkpoints in cancer tissues
Patient characteristics of ICC from the affiliated cancer hospital of Zhengzhou university
Characteristics | No. of patients | % |
---|---|---|
Gender | ||
Male | 47 | 58.02 |
Female | 34 | 41.98 |
Age (years) | ||
Median | 61 | |
Range | 44 ~ 82 | |
ECOG PS | ||
0 | 37 | 45.68 |
1 | 44 | 54.32 |
Size of primary tumor(cm) | ||
≥ 5 | 7 | 8.64 |
< 5 | 74 | 91.36 |
Histopathological grading | ||
High | 6 | 7.41 |
Intermediate-high | 5 | 6.17 |
Intermediate | 33 | 40.74 |
Intermediate-low | 24 | 29.63 |
Low | 13 | 16.05 |
TNM stage | ||
I | 45 | 55.56 |
II | 9 | 11.11 |
III | 27 | 33.33 |
Lymph node invasion | ||
Yes | 16 | 19.75 |
No | 65 | 80.25 |
Microvascular invasion | ||
Yes | 17 | 20.99 |
No | 64 | 79.01 |
HBV infection | ||
Yes | 20 | 24.69 |
No | 61 | 75.31 |
HCV infection | ||
Yes | 2 | 2.47 |
No | 79 | 97.53 |
Liver cirrhosis | ||
Yes | 10 | 12.35 |
No | 71 | 87.65 |
Child–Pugh grade | ||
A | 14 | 17.28 |
B | 67 | 82.72 |
CEA (ng/mL) | ||
≥ 10 | 7 | 8.64 |
< 10 | 74 | 91.36 |
CA199(U/mL) | ||
≥ 60 | 62 | 76.54 |
< 60 | 19 | 23.46 |
CA724(U/mL) | ||
≥ 14 | 55 | 67.90 |
< 14 | 26 | 32.10 |
ALT(U/L) | ||
≥ 80 | 56 | 69.14 |
< 80 | 25 | 30.86 |
AST(U/L) | ||
≥ 70 | 50 | 61.73 |
< 70 | 31 | 38.27 |
Total bilirubin(umol/L) | ||
≥ 42 | 69 | 85.19 |
< 42 | 12 | 14.81 |
Direct bilirubin(umol/L) | ||
≥ 16 | 72 | 88.89 |
< 16 | 9 | 11.11 |
Indirect bilirubin(umol/L) | ||
≥ 30 | 49 | 60.49 |
< 30 | 32 | 39.51 |
Highly and differentially expressed phagocytosis checkpoints in ICCs
Relationship between phagocytosis checkpoints and clinicopathologic features of ICCs
Characteristics (No. of patients) | CD68 hi | CD68 low | P-value |
---|---|---|---|
Gender | |||
Male | 30 | 17 | |
Female | 20 | 14 | 0.647 |
Age(years) | |||
≥ 60 | 20 | 18 | |
< 60 | 30 | 13 | 0.113 |
ECOG PS | |||
0 | 23 | 14 | |
1 | 27 | 17 | 0.941 |
Size of primary tumor (cm) | |||
≥ 5 | 3 | 4 | |
< 5 | 47 | 27 | 0.282 |
Histopathological grading | |||
Low | 24 | 13 | |
Intermediate to high | 26 | 18 | 0.594 |
TNM stage | |||
I + II | 26 | 28 | |
III | 24 | 3 | 0 |
Lymph node invasion | |||
Yes | 14 | 2 | |
No | 36 | 29 | 0.018 |
Microvascular invasion | |||
Yes | 16 | 1 | |
No | 34 | 30 | 0.002 |
HBV | |||
Yes | 18 | 2 | |
No | 32 | 29 | 0.003 |
HCV | |||
Yes | 1 | 1 | |
No | 49 | 30 | 0.73 |
Liver cirrhosis | |||
Yes | 4 | 6 | |
No | 46 | 25 | 0.131 |
Child–Pugh grade | |||
A | 4 | 10 | |
B | 46 | 21 | 0.005 |
CEA (ng/mL) | |||
≥ 10 | 4 | 3 | |
< 10 | 46 | 28 | 0.794 |
CA199(U/mL) | |||
≥ 60 | 36 | 26 | |
< 60 | 14 | 5 | 0.138 |
CA724(U/mL) | |||
≥ 14 | 35 | 20 | |
< 14 | 15 | 11 | 0.607 |
ALT(U/L) | |||
≥ 80 | 37 | 19 | |
< 80 | 13 | 12 | 0.229 |
AST(U/L) | |||
≥ 70 | 30 | 20 | |
< 70 | 20 | 11 | 0.684 |
Total bilirubin (umol/L) | |||
≥ 42 | 44 | 25 | |
< 42 | 6 | 6 | 0.365 |
Direct bilirubin (umol/L) | |||
≥ 16 | 46 | 26 | |
< 16 | 4 | 5 | 0.258 |
Indirect bilirubin (umol/L) | |||
≥ 30 | 33 | 16 | |
< 30 | 17 | 15 | 0.198 |
Characteristics (No. of patients) | SIRPαhi | SIRPαlow | P-value |
---|---|---|---|
Gender | |||
Male | 26 | 21 | |
Female | 16 | 18 | 0.463 |
Age (years) | |||
≥ 60 | 17 | 21 | |
< 60 | 25 | 18 | 0.228 |
ECOG PS | |||
0 | 19 | 18 | |
1 | 23 | 21 | 0.934 |
Size of primary tumor(cm) | |||
≥ 5 | 3 | 4 | |
< 5 | 39 | 35 | 0.618 |
Histopathological grading | |||
Low | 20 | 17 | |
Intermediate to high | 22 | 22 | 0.716 |
TNM stage | |||
I + II | 22 | 32 | |
III | 20 | 7 | 0.005 |
Lymph node invasion | |||
Yes | 14 | 2 | |
No | 28 | 37 | 0.001 |
Microvascular invasion | |||
Yes | 15 | 2 | |
No | 27 | 37 | 0.001 |
HBV | |||
Yes | 17 | 3 | |
No | 25 | 36 | 0.001 |
HCV | |||
Yes | 1 | 1 | |
No | 41 | 38 | 0.958 |
Liver cirrhosis | |||
Yes | 4 | 6 | |
No | 38 | 33 | 0.423 |
Child–Pugh grade | |||
A | 2 | 12 | |
B | 40 | 27 | 0.002 |
CEA (ng/mL) | |||
≥ 10 | 4 | 3 | |
< 10 | 38 | 36 | 0.769 |
CA199(U/mL) | |||
≥ 60 | 30 | 32 | |
< 60 | 12 | 7 | 0.26 |
CA724(U/mL) | |||
≥ 14 | 30 | 25 | |
< 14 | 12 | 14 | 0.48 |
ALT(U/L) | |||
≥ 80 | 31 | 25 | |
< 80 | 11 | 14 | 0.345 |
AST(U/L) | |||
≥ 70 | 26 | 24 | |
< 70 | 16 | 15 | 0.75 |
Total bilirubin (umol/L) | |||
≥ 42 | 36 | 33 | |
< 42 | 6 | 6 | 0.889 |
Direct bilirubin (umol/L) | |||
≥ 16 | 38 | 34 | |
< 16 | 4 | 5 | 0.637 |
Indirect bilirubin (umol/L) | |||
≥ 30 | 28 | 21 | |
< 30 | 14 | 18 | 0.238 |
Characteristics (No. of patients) | PD1hi | PD1low | P-value |
---|---|---|---|
Gender | |||
Male | 28 | 19 | |
Female | 18 | 16 | 0.552 |
Age(years) | |||
≥ 60 | 20 | 18 | |
< 60 | 26 | 17 | 0.478 |
ECOG PS | |||
0 | 23 | 14 | |
1 | 23 | 21 | 0.371 |
Size of primary tumor (cm) | |||
≥ 5 | 4 | 3 | |
< 5 | 42 | 32 | 0.984 |
Histopathological grading | |||
Low | 20 | 17 | |
Intermediate to high | 26 | 18 | 0.649 |
TNM stage | |||
I + II | 24 | 30 | |
III | 22 | 5 | 0.002 |
Lymph node invasion | |||
Yes | 13 | 3 | |
No | 33 | 32 | 0.027 |
Microvascular invasion | |||
Yes | 11 | 6 | |
No | 35 | 29 | 0.459 |
HBV | |||
Yes | 18 | 2 | |
No | 28 | 33 | 0.001 |
HCV | |||
Yes | 1 | 1 | |
No | 45 | 34 | 0.844 |
Liver cirrhosis | |||
Yes | 6 | 4 | |
No | 40 | 31 | 0.827 |
Child–Pugh grade | |||
A | 6 | 8 | |
B | 40 | 27 | 0.247 |
CEA (ng/mL) | |||
≥ 10 | 5 | 2 | |
< 10 | 41 | 33 | 0.413 |
CA199(U/mL) | |||
≥ 60 | 32 | 30 | |
< 60 | 14 | 5 | 0.089 |
CA724(U/mL) | |||
≥ 14 | 34 | 21 | |
< 14 | 12 | 14 | 0.184 |
ALT(U/L) | |||
≥ 80 | 33 | 23 | |
< 80 | 13 | 12 | 0.561 |
AST(U/L) | |||
≥ 70 | 30 | 20 | |
< 70 | 16 | 15 | 0.459 |
Total bilirubin (umol/L) | |||
≥ 42 | 38 | 31 | |
< 42 | 8 | 4 | 0.454 |
Direct bilirubin (umol/L) | |||
≥ 16 | 42 | 30 | |
< 16 | 4 | 5 | 0.428 |
Indirect bilirubin (umol/L) | |||
≥ 30 | 30 | 19 | |
< 30 | 16 | 16 | 0.319 |
Prognostic implications of phagocytosis checkpoints in ICC patients
Parameters | Hazard ratio | DFS | Hazard ratio | OS | ||
---|---|---|---|---|---|---|
95% CI | P-value | 95% CI | P-value | |||
TNM stage (I + IIVS.III) | 1.65 | (1.51, 2.16) | 0.678 | 1.81 | (1.32–2.45) | 0.505 |
Lymph node invasion (yes vs no) | 2.46 | (1.29, 4.78) | < 0.001 | 2.86 | (1.84–5.13) | < 0.001 |
Microvascular invasion (yes vs no) | 1.87 | (1.31–1.96) | 0.728 | 1.63 | (1.35–1.88) | 0.285 |
HBV (yes vs no) | 2.13 | (1.45–4.23) | < 0.001 | 1.91 | (1.63–4.15) | < 0.001 |
Child–Pugh grade (A vs. B) | 1.84 | (1.47–1.91) | 0.123 | 1.21 | (0.99–1.64) | 0.415 |
CD68 (high VS low) | 2.95 | (1.87–4.65) | < 0.001 | 3.08 | (1.95–4.87) | < 0.001 |
SIRPα (high VS low) | 3.06 | (1.86–5.02) | < 0.001 | 3.23 | (1.96–5.35) | < 0.001 |
PD1 (high VS low) | 2.39 | (1.52–3.78) | < 0.001 | 2.36 | (1.50–3.72) | < 0.001 |
CD68/SIRPα (double high VS others) | 2.38 | (0.77–7.36) | 0.0251 | 5.05 | (1.46–17.45) | 0.0203 |
CD68/PD1 (double high VS others) | 2.02 | (1.04–3.94) | 0.0682 | 2.12 | (1.08–4.15) | 0.0495 |
Parameters | Hazard ratio | DFS | Hazard ratio | OS | ||
---|---|---|---|---|---|---|
95% CI | P-value | 95% CI | P-value | |||
Lymph node invasion (yes vs no) | 1.17 | (0.824, 1.427) | 0.612 | 1.54 | (1.16–1.74) | 0.308 |
HBV (yes vs no) | 0.89 | (0.45–1.23) | 0.358 | 0.91 | (0.63–1.15) | 0.546 |
CD68 (high vs low) | 1.58 | (0.96–2.89) | 0.002 | 2.11 | (1.38–3.65) | 0.001 |
SIRPα (high vs low) | 1.78 | (1.37–4.02) | 0.003 | 1.55 | (0.98–3.54) | 0.004 |
PD1 (high vs low) | 1.39 | (1.35–2.66) | 0.006 | 1.49 | (1.14–2.68) | 0.006 |
CD68/SIRPα (double high vs others) | 1.28 | (0.81–6.25) | 0.016 | 2.16 | (1.15–4.85) | 0.018 |
CD68/PD1 (double high vs others) | – | – | – | 1.89 | (1.18–3.66) | 0.034 |